LFG
RCUS icon

Larson Financial Group’s Arcus Biosciences RCUS Stock Holding History

Larson Financial Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$454 Sell
21
-9
-30% -$194 ﹤0.01% 3329
2025
Q4 		$715 Buy
30
+18
+150% +$367 ﹤0.01% 3036
2025
Q3 		$163 Sell
12
-5
-29% -$52 ﹤0.01% 3283
2025
Q2 		$138 Buy
+17
New +$145 ﹤0.01% 3125

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Larson Financial Group's RCUS Position: Q1 2026 in Review

Larson Financial Group reduced its Arcus Biosciences (RCUS) stake by 30% in Q1 2026, selling an estimated $194 and leaving 21 shares worth $454. The position accounts for ﹤0.01% of the portfolio, ranked #3329.

Larson Financial Group first reported a position in RCUS in Q2 2025 and has held it in 4 quarters since. The position peaked at $715 in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Larson Financial Group held 21 shares of Arcus Biosciences worth $454 as of Q1 2026.
  • Larson Financial Group sold 9 Arcus Biosciences shares in Q1 2026, an estimated $194.
  • Arcus Biosciences made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3329 holding.
  • Larson Financial Group first reported a position in Arcus Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Larson Financial Group's Arcus Biosciences position peaked at $715 in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.